Over 600 sites across Asia-Pacific have been involved in the clinical development of now approved IO drugs, and hundreds more are experienced in managing clinical trials with immunotherapies for both monotherapy and combination therapies. This report aims at highlighting the main considerations for biotechnology companies when planning for IO drug clinical trials, and why Asia-Pacific is a key destination to conduct such trials.